Detecting Signs of Impending Heart Attack Before It Happens
When someone is at risk of an impending heart attack, or is in the midst of one, there are elevated levels of cardiac markers in his or her blood that can predict it. Fast detection of these cardiac markers by physicians in a variety of health care settings not only prevents heart attacks through initiation of treatment, but also facilitates treatment of patients in the throes of a cardiac event. Maxwell Sensors, Inc., a leading bio-medical research and development company that is committed to “MAXimizing WELLness” through the development of advanced bio-molecular testing systems, turned to Nectar to create a miniaturized, self-contained, microfluidic cartridge-based system that can quickly, accurately, and simultaneously identify all three cardiac markers.
Identifying All Three Cardiac Markers Quickly
Nectar faced the challenges of designing and engineering a system that can quickly identify levels of the three leading cardiac markers—Troponin, a protein that becomes elevated with myocardial damage; Creatine Kinase (CK-MB) an enzyme associated with myocardial infarction; and Myoglobin, the primary oxygen-carrying pigment in muscle tissue, which is an indication of muscle damage, including damage to the heart muscle. The system had to utilize the MCL-disc, a sensor that uses the chemiluminescence method, one of the most sensitive and established optical detection principles used in laboratory immunoassay systems, and be compact enough to fit a desktop footprint.
Developing the MCL Immunoassay Platform
Nectar developed a simple, elegant design for the MCL Immunoassay Platform for Cardiac Marker Test. In addition to deploying Maxwell Sensors’ proprietary, self-contained, microfluidic MCL-disc technology in an automated, compact, low-cost platform, the firm’s design includes an enclosure and test door that is 100-percent impervious to environmental light. Making the unit lightproof was critical to protecting the accuracy and sensitivity of the optoelectronics utilized by the testing technology.
Improving Cardiac Diagnoses in Varied Patient Care Settings
The MCL Immunoassay Platform for Cardiac Marker Test satisfies growing demand for a single-point cardiac marker test methodology that can supplant the cost and delays associated with separate tests. The platform can provide rapid, accurate, and cost-effective diagnostic tests in all patient care settings, including intensive care units, operating rooms, critical care facilities, emergency rooms, physician’s offices, and clinics. By delivering an effective, functional design for the MCL Immunoassay Platform for Cardiac Marker Test, Nectar is helping Maxwell Sensors realize innovation through the introduction of a better option for cardiac diagnostic testing.